Urinary triaosylceramide (GB3) as a marker of cardiac disease

A method of treating cardiac disease in a human subject, comprising:

• obtaining and placing a urine sample from the human subject on a filter paper;
• drying the urine sample on the filter paper;
• extracting the dried urine sample with methanol;
• injecting a portion of the extracted urine sample into a LC-MS system along with a radio-labeled standard solution comprising a known concentration of the Gb3 in methanol;
• eluting the Gb3 in the urine sample and the standard solution with a methanol/water gradient;
• obtaining one or more peaks of the Gb3 in the urine sample and the standard solution in a mass spectrum from the LC-MS system;
• creating a calibration curve by plotting a peak area of the one or more peaks of Gb3 in the biological sample and the standard solutions against a retention time;
• calculating the level of the Gb3 in the urine sample by calculating a concentration of the Gb3 from the calibration curve;
• and
• if said calculated level of Gb3 in the urine sample is above 200 ng/ml, administering a pharmacological or chemical chaperone to the patient in a sufficient concentration to treat cardiac disease, wherein the human subject is selected from a healthy human subject, a non-Fabry disease patient, and a subject with no genetic predispositions towards Fabry's disease.